MGTXMeiraGTx Holdings plc
The Read
MeiraGTx historically reacts to regulatory catalysts with median absolute moves of about 35%.
The schedule
- Tue8Dec
Highly anticipated Phase 2 readout for radiation-induced xerostomia, which previously received FDA Breakthrough Therapy Designation.
- Sun7Feb
Q3 results serving as the final fundamental checkpoint before pivotal RIX topline data.
- Tue9Feb
Year-end earnings combined with official regulatory guidance and BLA filing timelines for AAV2-hAQP1.
- Tue11May
First-quarter financials alongside critical updates on the Phase 3 AAV-GAD Parkinson's program.
Past
- Tue6Oct
Update on patient enrollment and site activation for the Parkinson's gene therapy trial.
- Thu13Aug
Actual outcome: Bull · $13.52 at outcome
MeiraGTx received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 data for radiation-induced xerostomia on August 13. The earnings beat and regulatory milestone significantly boosted investor confidence in near-term commercial potential. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +97.3% from 2026-03-18 to 2026-08-14 (~3.0σ vs typical 75d vol). Target evaluation date 2026-09-14 (not yet reached as of 2026-08-14). Confidence 95%.
MeiraGTx received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 data for radiation-induced xerostomia on August 13. The earnings beat and regulatory milestone significantly boosted investor confidence in near-term commercial potential. [Market retrospective · Long-Term (31–75 days)] Missed anticipation: +97.3% from 2026-03-18 to 2026-08-14 (~3.0σ vs typical 75d vol). Target evaluation date 2026-09-14 (not yet reached as of 2026-08-14). Confidence 95%.
- Sun9Aug
Quarterly financials with a critical focus on cash runway following the recent Sanofi ROFN update and J&J bota-vec transaction.
- Thu25Jun
Actual outcome: Bull · $13.51 at outcome
MeiraGTx provided a favorable update regarding its Sanofi Riboswitch licensing agreement and right of first negotiation (ROFN). The market reacted positively to the advancement of this strategic partnership, as it reinforced confidence in the platform's commercial viability and potential for near-term milestone revenue, driving the stock 5% higher.
Potential execution of the Sanofi Riboswitch right of first negotiation (ROFN) or licensing milestone.
- Wed1Apr
Actual outcome: Bull · $8.97 at outcome
Price reached or exceeded bull target ($6.20) at outcome date.
Expected equity raise to fund the AAV-GAD Phase 3 trial and RIX pivotal studies. Market expects dilution, but the scale and pricing are the key variables.
- Mon30Mar
Actual outcome: Bear · $7.39 at outcome
MeiraGTx reported Q4 2025 financial results and announced an FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of radiation-induced xerostomia. Despite the positive pipeline development and an initial post-earnings jump, the stock ultimately declined 8.7% over the measurement period, likely pressured by a notable insider sale from the CEO and market digestion of the company's cash runway.
Release of fiscal year-end results with critical focus on the remaining $14.8M cash balance reported in the prior quarter.
- Tue24Mar
Actual outcome: Bull · $7.62 at outcome
MeiraGTx announced that the FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 to treat radiation-induced xerostomia alongside its Q4 and full-year 2025 financial results. The combination of this major regulatory milestone and reports of a significant earnings beat alleviated concerns over the company's cash runway and operational burn, driving the stock well past the bull target.
Annual report disclosure regarding remaining cash runway and operating burn. Given the Sep 2025 cash levels, guidance will likely confirm the immediate need for capital.
